Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,447,870
  • Shares Outstanding, K 190,777
  • Annual Sales, $ 2,854 M
  • Annual Income, $ 426,860 K
  • EBIT $ 484 M
  • EBITDA $ 572 M
  • 60-Month Beta 0.33
  • Price/Sales 4.82
  • Price/Cash Flow 22.19
  • Price/Book 2.43

Options Overview Details

View History
  • Implied Volatility 29.63% ( -0.73%)
  • Historical Volatility 26.77%
  • IV Percentile 42%
  • IV Rank 27.32%
  • IV High 48.42% on 08/05/24
  • IV Low 22.57% on 04/26/24
  • Put/Call Vol Ratio 0.68
  • Today's Volume 158
  • Volume Avg (30-Day) 1,413
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 37,657
  • Open Int (30-Day) 42,217

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.73
  • Number of Estimates 9
  • High Estimate 0.85
  • Low Estimate 0.49
  • Prior Year 0.49
  • Growth Rate Est. (year over year) +48.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.55 +11.00%
on 02/14/25
73.51 -4.04%
on 03/07/25
+4.68 (+7.11%)
since 02/12/25
3-Month
60.63 +16.35%
on 01/16/25
73.51 -4.04%
on 03/07/25
+4.28 (+6.46%)
since 12/12/24
52-Week
60.63 +16.35%
on 01/16/25
94.85 -25.63%
on 08/20/24
-14.64 (-17.19%)
since 03/12/24

Most Recent Stories

More News
1 Healthcare Stock to Target This Week and 2 to Turn Down

1 Healthcare Stock to Target This Week and 2 to Turn Down

PACB : 1.2800 (-2.29%)
VTRS : 9.24 (-1.07%)
BMRN : 70.54 (+0.07%)
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

MYGN : 10.41 (+1.56%)
BMRN : 70.54 (+0.07%)
GILD : 113.99 (-0.38%)
ABBV : 212.06 (-0.72%)
MRNA : 35.01 (+3.70%)
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC

Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients...

BMRN : 70.54 (+0.07%)
GILD : 113.99 (-0.38%)
BMY : 59.81 (-2.76%)
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study

Eli Lilly LLY and partner Incyte INCY announced that a late-stage study evaluating oral baricitinib in adolescent patients (aged 12-18) with severe alopecia areata (AA) showed clinically meaningful improvements...

BMRN : 70.54 (+0.07%)
LLY : 821.86 (-0.27%)
INCY : 67.73 (-0.50%)
GILD : 113.99 (-0.38%)
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults

Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in adults.As a...

BMRN : 70.54 (+0.07%)
GILD : 113.99 (-0.38%)
RHHBY : 43.5600 (+3.71%)
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

SRPT : 99.77 (-0.93%)
MYGN : 10.41 (+1.56%)
BMRN : 70.54 (+0.07%)
ABBV : 212.06 (-0.72%)
MRNA : 35.01 (+3.70%)
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug

Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).The...

BMRN : 70.54 (+0.07%)
GILD : 113.99 (-0.38%)
REGN : 689.50 (-3.99%)
RHHBY : 43.5600 (+3.71%)
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency has adopted a positive opinion for the label expansion of Fabhalta ((iptacopan).Fabhalta...

BMRN : 70.54 (+0.07%)
NVS : 108.64 (+1.08%)
GILD : 113.99 (-0.38%)
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect

Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect

SRPT : 99.77 (-0.93%)
MYGN : 10.41 (+1.56%)
BMRN : 70.54 (+0.07%)
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings

What To Expect From United Therapeutics’s (UTHR) Q4 Earnings

MYGN : 10.41 (+1.56%)
BMRN : 70.54 (+0.07%)
UTHR : 307.09 (+0.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder),...

See More

Key Turning Points

3rd Resistance Point 72.21
2nd Resistance Point 71.52
1st Resistance Point 71.03
Last Price 70.54
1st Support Level 69.84
2nd Support Level 69.15
3rd Support Level 68.66

See More

52-Week High 94.85
Fibonacci 61.8% 81.78
Fibonacci 50% 77.74
Fibonacci 38.2% 73.70
Last Price 70.54
52-Week Low 60.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar